Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 5
1999 1
2000 1
2001 1
2002 3
2003 4
2006 3
2007 2
2008 3
2009 4
2010 4
2011 6
2012 5
2013 6
2014 8
2015 6
2016 6
2017 7
2018 4
2019 4
2020 1
2021 4
2022 3
2023 3
2024 6
2025 10
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Did you mean reb amipide (60 results)?
Efficacy of Rebamipide in the Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Mucosal Breaks: A Systematic Review and Meta-Analysis.
Cion RIA, Juyad IGA, Yasay EB. Cion RIA, et al. Am J Gastroenterol. 2026 Feb 1;121(2):526-533. doi: 10.14309/ajg.0000000000003535. Epub 2025 May 14. Am J Gastroenterol. 2026. PMID: 40366001
Rebamipide is also comparable with the standard PPIs in preventing NSAID-induced mucosal breaks (RR 1.00, 95% CI 0.51-1.95, P = 1.00). ...DISCUSSION: Rebamipide is effective in preventing NSAID-induced GI mucosal breaks. Rebamipide may also be as good as the …
Rebamipide is also comparable with the standard PPIs in preventing NSAID-induced mucosal breaks (RR 1.00, 95% CI 0.51-1.95, P = 1.00) …
Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis.
Liu J, Xiong Z, Geng X, Cui M. Liu J, et al. Biomed Res Int. 2020 Sep 28;2020:7196782. doi: 10.1155/2020/7196782. eCollection 2020. Biomed Res Int. 2020. PMID: 33062694 Free PMC article.
OBJECTIVE: To contrast the effect of rebamipide with proton pump inhibitors (PPIs) versus PPIs alone for the treatment of endoscopic submucosal dissection (ESD-) induced ulcers. ...In addition, rebamipide plus PPI therapy was discovered to be significantly more effe …
OBJECTIVE: To contrast the effect of rebamipide with proton pump inhibitors (PPIs) versus PPIs alone for the treatment of endoscopic …
Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis.
Yan YL, Chang JY, Ling XR, Xue CY. Yan YL, et al. J Ocul Pharmacol Ther. 2024 Dec;40(10):629-637. doi: 10.1089/jop.2024.0098. Epub 2024 Oct 25. J Ocul Pharmacol Ther. 2024. PMID: 39450472
Purpose: To evaluate the effects of rebamipide ophthalmic suspension on optical quality and efficacy of patients with dry eye under different conditions. ...Conclusions: These results indicate a significant improvement in the efficacy of rebamipide treatment for pat …
Purpose: To evaluate the effects of rebamipide ophthalmic suspension on optical quality and efficacy of patients with dry eye under d …
Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis.
Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Jaafar MH, et al. Dig Dis Sci. 2018 May;63(5):1250-1260. doi: 10.1007/s10620-017-4871-9. Epub 2017 Dec 1. Dig Dis Sci. 2018. PMID: 29192375
OBJECTIVE: The role of gastritis in dyspepsia remains controversial. We aimed to examine the efficacy of rebamipide, a gastric mucosal protective agent, in both organic and functional dyspepsia. ...Overall, dyspepsia symptom improvement was significantly better with reb …
OBJECTIVE: The role of gastritis in dyspepsia remains controversial. We aimed to examine the efficacy of rebamipide, a gastric mucosa …
The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study.
Oh DJ, Yoon H, Kim HS, Choi YJ, Shin CM, Park YS, Kim N, Lee DH, Ha YJ, Kang EH, Lee YJ, Kim N, Kim KJ, Liu F. Oh DJ, et al. Korean J Intern Med. 2022 Nov;37(6):1153-1166. doi: 10.3904/kjim.2021.216. Epub 2022 Nov 1. Korean J Intern Med. 2022. PMID: 36375487 Free PMC article. Clinical Trial.
This study investigated the associations between efficacy, safety, and gastrointestinal symptoms linked to rebamipide and proton pump inhibitor administration in patients requiring long-term NSAID use. ...Furthermore, fewer side-effects emerged with rebamipide....
This study investigated the associations between efficacy, safety, and gastrointestinal symptoms linked to rebamipide and proton pump …
Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis.
Zhang S, Qing Q, Bai Y, Mao H, Zhu W, Chen Q, Zhang Y, Chen Y. Zhang S, et al. Dig Dis Sci. 2013 Jul;58(7):1991-2000. doi: 10.1007/s10620-013-2606-0. Epub 2013 Feb 28. Dig Dis Sci. 2013. PMID: 23456504
Randomized controlled trials (RCTs) recruiting subjects with co-prescriptions of NSAIDs and rebamipide were eligible. Efficacy and safety of rebamipide were reevaluated, and dichotomous data were pooled to obtain relative risk (RR) with a 95 % confidence interval. . …
Randomized controlled trials (RCTs) recruiting subjects with co-prescriptions of NSAIDs and rebamipide were eligible. Efficacy and sa …
Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial.
Abdelaziz A, Shamma RN, Fayed HL, Ali S. Abdelaziz A, et al. Clin Oral Investig. 2025 Feb 1;29(2):106. doi: 10.1007/s00784-025-06159-x. Clin Oral Investig. 2025. PMID: 39891768 Free PMC article. Clinical Trial.
MATERIALS AND METHODS: Patients were divided randomly into three parallel arms: 1% Rebamipide; 1% nanoparticulated Rebamipide, Clobetasol propionate. The outcome measures included WHO oral mucositis grading, pain (NRS), ulcer size, and healing time. ...CLINICAL RELE …
MATERIALS AND METHODS: Patients were divided randomly into three parallel arms: 1% Rebamipide; 1% nanoparticulated Rebamipide, …
Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study.
Kang D, Choi MG, Shim KN, Jung HK, Nam SJ, Park JH, Kim SG, Kim NH, Hong SJ, Jeon TJ, Chung JI, Lee HL, Lee JY, Kim TO, Lee CM, Kim SM, Kim JH, Kim JE, Moon JS, Kim HD, Lee WS, Park HJ. Kang D, et al. World J Gastroenterol. 2024 Dec 28;30(48):5152-5161. doi: 10.3748/wjg.v30.i48.5152. World J Gastroenterol. 2024. PMID: 39735267 Free PMC article. Clinical Trial.
BACKGROUND: For the treatment of gastritis, rebamipide, a mucoprotective agent, and nizatidine, a gastric acid suppressant, are commonly employed individually. ...No adverse events related to the drugs were observed. CONCLUSION: Rebamipide/nizatidine combination is …
BACKGROUND: For the treatment of gastritis, rebamipide, a mucoprotective agent, and nizatidine, a gastric acid suppressant, are commo …
Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy for ESD induced gastric ulcers a randomized multicenter study.
Yang YJ, Lim H, Lee JG, Oh CK, Kim TW, Lee SP, Seo SI, Kim YJ, Bang CS, Shin WG, Kim JB, Jang HJ, Baik GH, Kae SH. Yang YJ, et al. Sci Rep. 2025 Jul 25;15(1):27127. doi: 10.1038/s41598-025-11964-1. Sci Rep. 2025. PMID: 40715454 Free PMC article. Clinical Trial.
Currently, no consensus exists on optimal treatment for post-endoscopic submucosal dissection (ESD) gastric ulcer. This study aims to compare rebamipide and tegoprazan combination therapy with tegoprazan monotherapy for post-ESD ulcer healing. ...The proportion of flat ulc …
Currently, no consensus exists on optimal treatment for post-endoscopic submucosal dissection (ESD) gastric ulcer. This study aims to compar …
Safety and efficacy of rebamipide compared to artificial tears for the treatment of dry eye: a systematic review and meta-analysis.
Chiu CW, Tam KW, Lin IC. Chiu CW, et al. BMC Ophthalmol. 2025 May 27;25(1):317. doi: 10.1186/s12886-025-04146-0. BMC Ophthalmol. 2025. PMID: 40426110 Free PMC article.
BACKGROUND: Rebamipide (RBM) is a novel drug that increases mucin secretion on the ocular surface. Nevertheless, the therapeutic efficacy of topical RBM for dry eye disease (DED) treatment remains inconclusive. ...
BACKGROUND: Rebamipide (RBM) is a novel drug that increases mucin secretion on the ocular surface. Nevertheless, the therapeutic effi …
99 results